ÂÜÀòÂÒÂ×

Bill Fricker is a seasoned finance executive with extensive experience in leading financial operations for various companies in the pharmaceutical and biopharmaceutical sectors. Currently serving as Chief Financial Officer at NeuroTrauma Sciences, LLC, Bill is responsible for preparing the company for public offering. Previous roles include Consulting Chief Financial Officer at LS Associates and Chief Financial Officer at Eleison Pharmaceuticals Inc., where efforts to go public were hindered by market conditions. Bill successfully led NRx Pharmaceuticals, Inc. through a public offering via SPAC acquisition in May 2021. Other significant positions held include Vice President of Finance & Principal Accounting Officer at Immunomedics, Global Controller and Chief Accounting Officer at JM Huber, and Director of Policies and Controls at Tyco International. Bill’s career also features roles at Johnson & Johnson and Bristol-Myers Squibb, contributing to expertise in financial management, compliance, and strategic oversight. Educational qualifications include an MBA in Finance from Villanova University and a BS in Accounting from Penn State University.